PLAU and breast carcinoma: The determination of uPA and PAI-1 concentration in tumor tissue by enzyme-linked immunosorbent assay (ELISA) is the first prospectively validated biomarker in early breast cancer with level of evidence (LOE) 1A, following the systematics of Hayes et al [7].